Home › NCT06467825
Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent
Who can join
Ages 25 to 55 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: • Pass a test subject screening facility modified Air Force Class III physical Exclusion Criteria: * Known allergy to furosemide or sulfa drugs * Currently taking drugs or medications known to adversely interact with furosemide, including but not limited to aspirin, NSAIDs, antibiotics, or immunosuppressant drugs * Systemic diseases or current medications known to influence the cardiovascular system * Renal disease * Type II Diabetes * Pregnant participants will be excluded (a urine pregnancy screen will be made available).
About the study
The purpose of Lunar OI (Orthostatic Intolerance) is to determine if there are differences between males and females in tolerance to and cardiovascular responses during different angles of head-up tilt simulating gravity levels less than or equal to Earth's gravity. Also, this study will determine if a gradient compression garment affects tolerance to tilting and the cardiovascular stress at different tilt angles. Males and females are being identified by biological sex. This will be a two-phased study design. In Phase I we will determine whether there are differences in the development of signs or symptoms of orthostatic intolerance between males and females when tilted head up on a table to different angles to simulate gravity levels that astronauts may experience when landing on or launching from the surface of the Moon. In Phase II, the tilt tests simulating the same gravity levels from Phase I will be repeated, but a custom-made lower-body compression garment will be worn to see if wearing the garment affects the development of orthostatic intolerance. For both study phases, before tilting, a drug will be administered to reduce the amount fluid in the blood (plasma) to levels similar to that experienced by astronauts during spaceflight.
What is being tested
- Potassium Supplement (drug)
- Furosemide 20 MG (drug)
- Compression Garment (device)
Sponsor: National Aeronautics and Space Administration (NASA) · Participants: 38 · Started: Aug 9, 2022
Contact the study team
- Jason R Lytle, PhD · Phone: 281-483-9531
Official record on ClinicalTrials.gov — NCT06467825
Locations in the U.S.
| Texas | NASA, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.